The METIS trial is intended for patients who have recently been diagnosed with brain metastases from non-small cell lung cancer (NSCLC). This clinical trial is evaluating the safety and efficacy of the NovoTTF-100M System for this indication, when added after the standard stereotactic radiosurgery (SRS) normally given to patients in this condition. This System delivers Tumor Treating Fields (TTFields) to the cancer in the brain. Novocure Ltd., the trial sponsor, maintains this website to help patients get basic information about the clinical trial and facilitate their accessibility to medical centers that offer participation in the trial. If you would like to take part in the METIS trial, please contact one of the participating centers  as soon as possible. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor.